Free tool
FAERS Monitor: Yeztugo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220020 or its brand name (Yeztugo, Lenacapavir Sodium). Reports on generic versions are filed under their own applications.
Reports
506
Serious
127
25% of reports
Hospitalization
12
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site discharge149
- injection site pain141
- injection site nodule113
- injection site erythema43
- injection site mass37
- injection site swelling24
- injection site cellulitis17
- loss of consciousness16
- injection site bruising15
- injection site reaction14
- syncope13
- nausea12
- vomiting12
- dizziness10
- injection site discomfort10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 367 |
| 2026 | 138 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,653 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site dischargeSignal | 149 | 1184.5 | 1032.3 | 170,208 |
| injection site noduleSignal | 113 | 431.2 | 366.2 | 47,606 |
| injection site cellulitisSignal | 17 | 383.8 | 240.0 | 6,058 |
| injection site massSignal | 37 | 41.6 | 30.5 | 1,428 |
| injection site discomfortSignal | 10 | 39.6 | 21.4 | 338 |
| injection site painSignal | 141 | 19.1 | 16.6 | 2,437 |
| injection site erythemaSignal | 43 | 14.4 | 10.8 | 526 |
| injection site swellingSignal | 24 | 13.0 | 8.8 | 255 |
| injection site reactionSignal | 14 | 8.5 | 5.0 | 85 |
| injection site bruisingSignal | 15 | 7.8 | 4.7 | 83 |
| syncopeSignal | 13 | 5.4 | 3.2 | 43 |
| loss of consciousnessSignal | 16 | 5.2 | 3.2 | 50 |
| vomiting | 12 | 1.1 | 0.6 | 0 |
| dizziness | 10 | 0.8 | 0.5 | 0 |
| nausea | 12 | 0.6 | 0.4 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.